Sign Up for a Free Account


Book Review: "Brain on Fire: My Month of Madness" by Susannah Cahalan

Brain on Fire: My Month of Madness, authored by Susannah Cahalan, is more than just a memoir; it's a significant case study for neurologists, providing insights into the rare and often misdiagnosed condition of anti-NMDA receptor encephalitis. Released in 2012, the book chronicles Cahalan's descent into a seemingly psychiatric illness that was eventually diagnosed as a neurologic disorder, offering a profound exploration of the intersection between neurology, psychiatry, and the patient experience.

Content and scientific context

The narrative unfolds as Cahalan, a young journalist, starts experiencing bizarre symptoms, including paranoia, seizures, and hallucinations. Her condition deteriorates rapidly, leading to hospitalization and a series of misdiagnoses. The turning point comes when Dr. Souhel Najjar, using a simple yet effective test involving drawing a clock, suspects an underlying neurologic disorder. This eventually leads to the diagnosis of anti-NMDA receptor encephalitis, a type of autoimmune encephalitis.

Anti-NMDA receptor encephalitis is characterized by the body's immune system mistakenly attacking NMDA receptors in the brain. NMDA receptors are critical for synaptic transmission and plasticity, and their dysfunction can lead to a range of neurologic and psychiatric symptoms. The disease was relatively unknown at the time of Cahalan's illness, and her account sheds light on the complexities of diagnosing such rare neurologic disorders.

Relevance to neurologists

For neurologists, Brain on Fire is a compelling reminder of the importance of differential diagnosis, especially in cases where psychiatric symptoms mask an underlying neurologic condition. Cahalan’s narrative provides a vivid firsthand account of experiencing and recovering from a disease that many neurologists may encounter only a few times in their careers.

The book also emphasizes the role of immunotherapy in treating autoimmune encephalitis, highlighting the dramatic recovery patients can make with appropriate treatment. Cahalan’s recovery with the use of steroids, plasmapheresis, and intravenous immunoglobulin showcases the potential effectiveness of these treatments in autoimmune neurologic disorders.

Advancements in our understanding

Since the publication of Susannah Cahalan's Brain on Fire in 2012, there have been considerable advancements in defining, diagnosing, and understanding anti-NMDA receptor encephalitis.

  1. Improved definition and recognition. Anti-NMDA receptor encephalitis is now more widely recognized and understood within the medical community. It is characterized as an autoimmune disorder in which the body's immune system mistakenly targets NMDA (N-methyl-D-aspartate) receptors in the brain. These receptors are crucial for controlling synaptic plasticity and memory function.
  2. Diagnostic criteria and protocols. The diagnostic criteria for anti-NMDA receptor encephalitis have been refined. The detection of anti-NMDA receptor antibodies in cerebrospinal fluid is now a key diagnostic marker. This is often complemented by a range of tests, including MRI, EEG, and PET scans, to rule out other conditions and confirm the diagnosis.
  3. Understanding of symptoms and phases. The understanding of the clinical presentation of the disease has improved. Typically, the illness presents in stages, beginning with flu-like symptoms, followed by psychiatric symptoms (such as hallucinations and paranoia), and then progresses to seizures, movement disorders, and loss of consciousness. There is now greater awareness that the psychiatric symptoms can often lead to initial misdiagnosis as a psychiatric disorder.
  4. Treatment advancements. There have been significant strides in the treatment of anti-NMDA receptor encephalitis. First-line treatments typically include corticosteroids, intravenous immunoglobulin, and plasmapheresis to reduce the immune response. When patients do not respond to initial treatment, second-line therapies such as rituximab and cyclophosphamide are used. Early diagnosis and treatment have been shown to improve outcomes significantly.
  5. Research on causes and triggers. Research has progressed in understanding the potential causes and triggers of the disease. Although the exact cause is still unknown, it is believed that in some cases, the condition may be triggered by an infection, tumor, or other immune challenges. There is ongoing research into the molecular mechanisms that lead to the development of the disease.
  6. Long-term outcome studies. Longer-term follow-up studies of patients have provided more information about the prognosis and potential long-term effects. Many patients who receive timely treatment can recover, but some may have residual cognitive and psychological issues. Rehabilitation therapies, including cognitive and physical therapy, are crucial in the recovery phase.
  7. Increased awareness and education. The disease has gained more visibility in both the medical field and the public domain, leading to better awareness. This has been crucial for earlier diagnosis and treatment. There's also a push for more education among healthcare professionals to recognize the signs and symptoms of the disease.

Brain on Fire is a must-read for neurologists, offering both a personal perspective and a clinical overview of a rare but important neurologic disorder. Cahalan’s story is a powerful narrative that humanizes the experience of psychiatric and neurologic illnesses and reinforces the importance of comprehensive diagnostic evaluation in neurology practice and the ongoing need for awareness and understanding of rare neurologic conditions.

MedLink acknowledges the use of GPT-4 in drafting this blog entry.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125